What it sells
Kernal is creating mRNA 2.0 therapies that work in specific cells
Business model breakdown
Buyer: who owns the budget?
Pharma and biotech partners who co-develop and license mRNA therapeutics; Kernal seeks tailored partnerships with companies sharing its vision.
Trigger: what makes them buy now?
Ex vivo cell therapies are slow to manufacture, costly and limited to specialized centers; in vivo programming aims to remove these barriers.
Workflow: what inputs become what output?
Deliver an mRNA sequence in targeted lipid nanoparticles to specific tissues and cells, with AI-designed sequences ensuring selective translation only in target cells, to program in vivo CAR-T cells for cancer and autoimmune disease.
Economics: what it saves and how it charges
Therapeutics developer: value from pipeline assets and partnerships; funded in part by an ARPA-H award of up to $48 million for lower-cost in vivo CAR T-cell therapies.
Distribution: how it reaches customers
Partnership-led: each partnership is tailored to the partner's expertise and program needs; contact via hello@kernalbio.com.
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| — | Y Combinator Summer 2020 | — | Y Combinator | ycombinator.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.